Full-Time

Transcend: Director

GTO Innovative Medicine Operate State

Posted on 7/11/2026

Deadline 7/19/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

€119.2k - €204.4k/yr

+ Bonus + Commissions

New Hope, PA, USA + 2 more

More locations: Cork, Ireland | Markham, ON, Canada

Hybrid

Three days on-site per week required.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Agile
Six Sigma
Data Governance
Data Analysis

Get referred to Johnson & Johnson

Find people who can refer or advise you

Requirements
  • Minimum of High School or equivalent diploma/degree is required; Bachelor's degree strongly preferred
  • Certifications are helpful in one or more of the following: PMP, FPX, or equivalent project management; APICS; and/or Lean/Six Sigma /Process Excellence
  • Minimum 10 years of relevant work experience
  • Business functional experience (i.e., Operations, Supply Chain, and/or Finance) working in a complex, multi-ERP / system environment
  • Experience in operating or supporting large-scale ERP processes following transformation/implementation programs
  • Experience in supporting, improving, developing, implementing, and leading operational technological processes within a global organization
  • Strong interpersonal, relationship building, and negotiating/influencing skills, with demonstrated ability to collaborate and communicate at various levels including program teams / execution and senior leadership / strategic levels
  • People management and development experience
  • Requires proficiency in English (written and verbal) to communicate effectively and professionally; proficiency in German, Dutch, or Italian is helpful
  • May require up to 50% domestic and international travel depending on work location and business needs
  • Requires the ability, through our flexible work policy, to work on-site a minimum of three days each week, with the option for two remote workdays each week
Responsibilities
  • Collaborate with the Functional template owners and Functional CoE, and lead the Governance process with respect to capability improvements
  • In partnership with Technology, sustain and manage the content & configuration elements of the system solution including process flows
  • Partner with Master Data and ensure Delivery of connected master data and transaction data excellence that support IM Operations
  • Ensure compliance with the IM and Transcend processes
  • Forge effective partnerships with IT, in the development of the connection points with the Integration layer and seamlessly connect to the enterprise architecture, visualization and analytics design
  • Work closely with the other Strategic Programs Lead to continuously embed best practice and agile methodologies in the support of IM Transcend system
  • Ensure support across functions is established and maintained for deployed capabilities
  • Leverage best practices across the enterprise, drive preventative action, enable enterprise/E2E knowledge-sharing and act as an escalation point for critical user issues
  • Develop sustainment infrastructure to oversee and assist Super Users in providing access and security controls support for the systems according to the defined processes
  • Establish a team of experts to provide system audit and inspection support
  • Ensure all support documentation aligns with the IM Quality Management System requirements, including creation, revision, review, and approval when it is required
  • Ensure Sustainment functional teams understand the impact systems standards and architecture changes will have on the template capabilities and the need to engage with the Change Control Board Create and maintain infrastructure of Change Control Boards
  • Facilitate Business Case justification for Continuous Improvement changes, and lead implementations ensuring business readiness through oversight of Business Adoption and Documentation/Training Partner with J&J Technology (JJT)
  • Consistently seek to establish best practices in Functional CoE engagement through actively participating in Continuous Improvement opportunities
  • Develop team resources that can achieve functional excellence and have the ability to become SMEs for multiple functional areas over time through participating in targeted development programs Partner with Transcend and IM colleagues
  • Collaborate with senior leaders to ensure design aligns strategies and roadmaps
  • Partner with global template team of Supply Chain experts in design, development, maintenance and improvement of global business processes and integration points
Desired Qualifications
  • Pharmaceuticals, Life Sciences, or other regulated industry experience
  • Experience with business process design, engineering, or optimization
  • Proven experience with large-scale SAP ERP replacement project(s)
  • Experience effectively leading and governing multi-functional decision-making bodies
  • Experience in deploying and/or improving standardized work processes, tools, and templates
  • Proficiency in English (written and verbal) to communicate effectively and professionally; proficiency in German, Dutch, or Italian is helpful

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
  • FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
  • J&J's 2026 revenue will exceed $100 billion for the first time in history.

What critics are saying

  • 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
  • Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
  • Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.

What makes Johnson & Johnson unique

  • J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
  • Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
  • J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
  • J&J's oncology portfolio gained multiple FDA approvals in early 2026.
  • MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-1%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

INACTIVE